Patrick Durez

13.1k total citations · 2 hit papers
205 papers, 7.2k citations indexed

About

Patrick Durez is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Patrick Durez has authored 205 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Rheumatology, 72 papers in Hematology and 52 papers in Genetics. Recurrent topics in Patrick Durez's work include Rheumatoid Arthritis Research and Therapies (159 papers), Autoimmune and Inflammatory Disorders Research (69 papers) and Systemic Lupus Erythematosus Research (53 papers). Patrick Durez is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (159 papers), Autoimmune and Inflammatory Disorders Research (69 papers) and Systemic Lupus Erythematosus Research (53 papers). Patrick Durez collaborates with scholars based in Belgium, United States and United Kingdom. Patrick Durez's co-authors include Paul Emery, Roy Fleischmann, Stephen Hall, Ronald Pedersen, René Westhovens, Andrew Koenig, Mark C. Genovese, Charles Peterfy, Peter Nash and Deborah Robertson and has published in prestigious journals such as The Lancet, The Journal of Experimental Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick Durez

192 papers receiving 7.0k citations

Hit Papers

Comparison of methotrexat... 2008 2026 2014 2020 2008 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
    2008 652 citations Stephen Hall, Patrick Durez et al. profile →
  2. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial
    2019 329 citations Charles Peterfy, Patrick Durez et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Patrick Durez 5.1k 2.4k 2.2k 1.3k 969 205 7.2k
Alain Cantagrel 5.3k 1.0× 1.9k 0.8× 2.0k 0.9× 861 0.7× 769 0.8× 202 7.5k
Maya H Buch 3.9k 0.8× 1.4k 0.6× 1.7k 0.8× 996 0.8× 1.1k 1.2× 211 6.4k
Thasia Woodworth 4.2k 0.8× 1.5k 0.6× 2.3k 1.0× 642 0.5× 760 0.8× 84 7.4k
Andrea Rubbert‐Roth 3.3k 0.7× 1.5k 0.6× 1.7k 0.7× 885 0.7× 565 0.6× 123 5.1k
Samuel H. Zwillich 5.3k 1.0× 2.8k 1.2× 1.8k 0.8× 1.7k 1.3× 740 0.8× 89 7.7k
David Gruben 4.4k 0.9× 2.5k 1.0× 1.5k 0.7× 1.4k 1.1× 546 0.6× 101 6.3k
Sriram Krishnaswami 3.9k 0.8× 2.2k 0.9× 1.4k 0.6× 1.3k 1.0× 489 0.5× 59 6.1k
Maria Greenwald 2.7k 0.5× 1.2k 0.5× 1.5k 0.7× 868 0.7× 694 0.7× 76 5.1k
Mahboob U. Rahman 3.8k 0.7× 1.6k 0.7× 1.4k 0.6× 912 0.7× 416 0.4× 85 5.8k
Xavier Le Loët 3.3k 0.7× 1.3k 0.5× 1.4k 0.6× 644 0.5× 617 0.6× 198 5.4k

Countries citing papers authored by Patrick Durez

Since Specialization
Citations

This map shows the geographic impact of Patrick Durez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Durez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Durez more than expected).

Fields of papers citing papers by Patrick Durez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Durez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Durez. The network helps show where Patrick Durez may publish in the future.

Co-authorship network of co-authors of Patrick Durez

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Durez. A scholar is included among the top collaborators of Patrick Durez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Durez. Patrick Durez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Natalucci, Francesco, et al.. (2025). Evolution from early to difficult-to-treat rheumatoid arthritis: incidence and risk factors in the ERA uclouvain Brussels cohort. Arthritis Research & Therapy. 27(1). 182–182. 1 indexed citations
2.
Natalucci, Francesco, et al.. (2024). Analysis of synovitis patterns in early RA supports the importance of joint-specific factors. Seminars in Arthritis and Rheumatism. 68. 152524–152524. 1 indexed citations
3.
Natalucci, Francesco, et al.. (2024). Sexual dysfunction in male patients treated with methorexate for arthritis: Analysis of the IIEF5 questionnaire and hormonal status. Joint Bone Spine. 91(4). 105716–105716. 1 indexed citations
4.
Tilman, Gaëlle, Axelle Loriot, Joëlle Marchandise, et al.. (2023). Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis. Annals of the Rheumatic Diseases. 82(12). 1538–1546. 7 indexed citations
5.
Kivitz, Alan, Alvin F. Wells, Herbert S. B. Baraf, et al.. (2023). Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study. Rheumatology and Therapy. 10(4). 901–915. 3 indexed citations
6.
Fusaro, Enrico, et al.. (2021). An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar. Immunotherapy. 14(3). 235–252. 4 indexed citations
7.
Durez, Patrick, Pedro C. Miranda, Antoaneta A. Toncheva, et al.. (2012). Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic. Arthritis & Rheumatism.
8.
Westhovens, René, Filip De Keyser, Е. Л. Насонов, et al.. (2011). A twelve-week exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
9.
Lenaerts, Jan, Bert Vander Cruyssen, Herman Mielants, et al.. (2011). A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study. Ghent University Academic Bibliography (Ghent University). 63. 1 indexed citations
10.
Haraoui, Boulos, Patrick Durez, Joan M. Bathon, et al.. (2010). Reduced Radiographic Progression in Patients with Early Rheumatoid Arthritis (RA) Treated with Abatacept plus Methotrexate Compared to Methotrexate Alone: 24 Month Outcomes. The Journal of Rheumatology. 37(6). 1328–1328. 2 indexed citations
11.
Haraoui, Boulos, Patrick Durez, René Westhovens, et al.. (2010). Disease Remission is Achieved Within Two Years In Over Half of Methotrexate Naive Patients with Early Erosive Rheumatoid Arthritis (RA) Treated with Abatacept Plus MTX: Results from The AGREE Trial. The Journal of Rheumatology. 37(6). 1287–1288. 5 indexed citations
12.
Emery, Paul, Patrick Durez, F C Breedveld, et al.. (2008). Clinical remission, radiographic non-progression, and normalized function with the combination of etanercept and methotrexate in the treatment of early active rheumatoid arthritis: 1-year results of the COMET trial. Digital Access to Libraries. 58(9). 1 indexed citations
13.
Kay, Jonathan, Patrick Durez, Eric L. Matteson, et al.. (2007). Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial. Annals of the Rheumatic Diseases. 66. 175–176. 2 indexed citations
14.
Durez, Patrick, René Westhovens, Filip Van den Bosch, et al.. (2006). Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition.. Ghent University Academic Bibliography (Ghent University). 1 indexed citations
15.
Burmester, Gerd R, Patrick Durez, Eric Ruderman, et al.. (2006). Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in rheumatoid arthritis patients with inadequate response to TNF inhibitors (REFLEX study). Annals of the Rheumatic Diseases. 65. 180–180. 5 indexed citations
16.
Cruyssen, Bert Vander, Patrick Durez, René Westhovens, et al.. (2006). Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect. Annals of the Rheumatic Diseases. 65. 349–349. 1 indexed citations
17.
Fleischman, Ross J., et al.. (2006). Lack of efficacy with 3 oral dose levels of TMI-005 (Apratastat), in subjects with active rheumatoid arthritis on a background of methotrexate-A phase 2 double-blind, placebo-controlled, parallel, randomized study. Annals of the Rheumatic Diseases. 65. 339–339. 3 indexed citations
18.
Houssiau, Frédéric, et al.. (2003). The effect of infliximab on rheumatoid nodules: A histopathological study. Annals of the Rheumatic Diseases. 62. 180–180. 2 indexed citations
19.
Snowden, John A., John J. Moore, Paul Cannell, et al.. (2001). Autologous stem cell transplantation in rheumatoid arthritis. eCite Digital Repository (University of Tasmania). 3 indexed citations
20.
Durez, Patrick, et al.. (1998). Methotrexate inhibits LPS-induced tumor necrosis factor production in vivo.. PubMed. 9(4). 669–72. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alain Cantagrel Breakdown of academic impact, for papers by Maya H Buch Breakdown of academic impact, for papers by Thasia Woodworth Breakdown of academic impact, for papers by Andrea Rubbert‐Roth Breakdown of academic impact, for papers by Samuel H. Zwillich Breakdown of academic impact, for papers by David Gruben Breakdown of academic impact, for papers by Sriram Krishnaswami Breakdown of academic impact, for papers by Maria Greenwald Breakdown of academic impact, for papers by Mahboob U. Rahman Breakdown of academic impact, for papers by Xavier Le Loët
Rankless by CCL
2026